Stocktoria
Xeris Biopharma Holdings, Inc. XERS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-06-21
Xeris Biopharma Holdings, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 8.5% | -16.6% | -26.8% | -74.3% | -232.2% |
| Net margin | 0.2% | -27.0% | -38.0% | -85.9% | -247.5% |
| FCF margin | — | — | — | — | -194.8% |
| Return on assets | 0.1% | -17.0% | -19.3% | -27.5% | -40.3% |
| Return on equity | 4.0% | 185.2% | 917.9% | -209.5% | -128.9% |
| Debt / equity | 16.10× | -7.84× | -28.15× | 4.14× | 0.92× |
| Current ratio | 2.19 | 1.67 | 1.64 | 2.54 | 1.80 |
| Revenue growth | 43.7% | 23.9% | 48.7% | 122.3% | 142.7% |
Source: SEC EDGAR filings · CIK 0001867096 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.